Compare Eaton Corporation plc (ETN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Incyte Corporation — how do they compare? Eaton Corporation plc trades at $462.65 (market cap $172.82B), while Incyte Corporation trades at $120.65 (market cap $24.54B). The key difference: Eaton Corporation plc is far larger — about 7× Incyte Corporation's market cap, and Eaton Corporation plc pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ETN | INCY | |
|---|---|---|
Market Cap | $172.82B | $24.54B |
Sector | Technology | Health |
52-Week High | $459.29 | $129.93 |
52-Week Low | $315.82 | $81.61 |
Enterprise Value | $193.45B | $20.04B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $463.70, up 4.21% over the past 24 hours, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and is approaching resistance at $467. Fundamentally, the company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating estimates of $3.07, and raised its full-year 2026 outlook. Revenue growth is robust, supported by surging data-center demand and a $7 million U.S. Air Force contract for grid security announced on August 6, 2026.
The outlook remains positive given Eaton's exposure to AI-driven power infrastructure spending, but the stock's premium valuation (P/E of 45.31) poses a risk if growth moderates. Analyst consensus is strongly bullish with a $499.75 price target, though investors should monitor execution risks and macroeconomic pressures that could impact the industrial sector.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
